A Phase 1 Study to Evaluate the Relative Bioavailability of a VX-828 Tablet Formulation
← catalyst calendarSponsored by Vertex Pharmaceuticals Incorporated (industry) · VRTX — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
68actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-04-01 | actual | When the study began enrolling |
| Primary completion | 2025-05-05 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-05-05 | actual | The whole study's end, after follow-up |
| First posted | 2025-03-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-06-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Cystic Fibrosis
Interventions
- Drug: VX-828
- Drug: VX-828
Primary outcomes
what the primary-completion date above is the date OFArea Under the Concentration Versus Time Curve from the Time of dosing to the Last Measurable Concentration (AUC0-tlast) of VX-828 in Plasma
measured From Day 1 up to Day 24
Maximum Observed Concentration (Cmax) of VX-828 in Plasma
measured From Day 1 up to Day 24
Permalink · VRTX's whole pipeline · Catalyst calendar · Every registered study · What changed